Ovarian Cancer Archives - Cancer Therapy Advisor

Use of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Has Doubled

By

Leah Lawrence

September 29, 2020

Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of

Gynecologic Cancer

Hyperthermic Intraperitoneal Chemotherapy May Improve Outcomes in Epithelial Ovarian Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

September 28, 2020

Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.

Fatigue can persist after cancer treatments.

Gynecologic Cancer

Clinically Significant Fatigue Common After Surgery for Gynecologic Cancers, Remains High 1 Year Later

By

Jessica Nye, PhD

September 14, 2020

Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.

The decade-long paradigm shift in decoding ovarian cancer is only now beginning to make its way from

Gynecologic Cancer

PARP Inhibitors Deemed Too Costly for Across-the-Board Frontline Maintenance in Ovarian Cancer

By

Leah Lawrence

September 11, 2020

Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.

Pre- or postmenopausal women with epithelial ovarian cancer can safely be treated with adjuvant horm

Gynecologic Cancer

Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer

By

Susan Moench, PhD, PA-C

September 3, 2020

Quality-adjusted progression-free survival (QA-PFS) represents an adjustment to PFS that incorporates patient-reported toxicity and other detrimental effects of treatment.

Gynecologic Cancer

Study Finds Patients With Rare Ovarian Cancer Develop Chemoresistance

By

Christina Bennett, MS

August 7, 2020

Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.

This article reviews the current evidence for the role of aromatase inhibitors (AIs) in the treatmen

Gynecologic Cancer

Longitudinal MicroRNAs Lacked Predictive Value in Ovarian Cancer

By

Leah Lawrence

July 30, 2020

Study results differ from prior research into microRNAs as predictive biomarkers.

Results of studies in ovarian cancer with agents bevacizumab and pazopanib has “raised the bar” for

Gynecologic Cancer

Study Suggests QoL Assessments Do Not Support First-Line Combination Chemotherapy With Weekly Paclitaxel for Epithelial Ovarian Cancer

By

Susan Moench, PhD, PA-C

July 21, 2020

This analysis focused on QoL end points associated with different dosing schedules for first-line carboplatin-paclitaxel in a predominantly European population with EOC.